- Home
- GASS vs VCRE Comparison
GASS vs VCRE Comparison
Compare GASS & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GASS | VCRE |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Greece | Sweden |
| Employees | N/A | 40 |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.4M | 316.4M |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GASS | VCRE |
|---|---|---|
| Price | $9.22 | $11.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 130.0K | 8.2K |
| Earning Date | 05-27-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.12 | $10.47 |
| 52 Week High | $10.55 | $13.15 |
Technical Indicators
Market Signals| Indicator | GASS | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 52.10 |
| Support Level | $9.09 | $10.75 |
| Resistance Level | $9.81 | $13.00 |
| Average True Range (ATR) | 0.30 | 0.63 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 11.81 | 56.05 |
Price Performance
Historical ComparisonAbout GASS StealthGas Inc.
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.